Eli Lilly suggests low-dose Zepbound and Foundayo could safely maintain weight loss at lower cost

New trial data indicate that lowering the dose of Eli Lilly's obesity injection Zepbound may still provide effective weight‑loss maintenance while improving safety.

The study also highlights Foundayo as another low‑dose candidate that could serve a similar maintenance role, offering a potentially cheaper alternative for patients.

If confirmed in larger studies, these options could broaden long‑term treatment strategies for individuals who have already lost weight with higher‑dose regimens.